CordLife India, a stem cell banking company, has taken an initiative to assist autistic patients who have stored their cord blood.
The company is extending its support to link patients in India in association with Duke Medicine research programme for such treatment.
Duke Medicine has been awarded $15 million to support an innovative research programme that explores the use of umbilical cord blood stem cells to treat autism, stroke, cerebral palsy and related brain disorders.
“Over the years, we have earned the trust of the parents to store their baby’s precious cord blood and cord lining with us. The Duke’s medicine research programme confirms our long held beliefs that the potential for future use of cord blood and cord lining will grow with the advancement in cell therapy,” Jeremy Yee, Chief Executive Officer of CordLife, was quoted in a release issued by the company.
The release says US data suggest that approximately one out of 50 babies suffer from autistic spectrum disorder. Boys are said to be five times more likely to have than girls. Treating autism costs $60,000 in a year on an average.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.